BBHC
INO icon

Brown Brothers Harriman & Co’s Inovio Pharmaceuticals INO Stock Holding History

Brown Brothers Harriman & Co’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3
Closed – – 1380
2022
Q3 		$0 Hold
3
– – ﹤0.01% 1540
2022
Q2 		$0 Buy
+3
New +$85 ﹤0.01% 1355

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Brown Brothers Harriman & Co's INO Position: Q4 2022 in Review

Brown Brothers Harriman & Co sold out of Inovio Pharmaceuticals (INO) in Q4 2022, closing a stake of 3 shares.

Brown Brothers Harriman & Co first reported a position in INO in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 183 funds tracked by Wall St. Rank hold INO as of Q4 2022.

  • Brown Brothers Harriman & Co reported no remaining Inovio Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 3 Inovio Pharmaceuticals shares in Q4 2022.
  • Brown Brothers Harriman & Co first reported a position in Inovio Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Brown Brothers Harriman & Co's Inovio Pharmaceuticals position peaked at $0 in Q3 2022.
  • 183 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2022, filed 9 Feb 2023.